Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. 2021

Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substances Discovery and Drugability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

As abnormal PI3K signaling is a feature of many types of cancer, the development of orally active PI3K inhibitors is of great significance for targeted cancer therapy. Through integrating strategies of reducing aromatic character/increasing the fraction of sp3 carbons together with scaffold hopping, we designed and synthesized two new series of thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives for use as PI3K inhibitors. Our structure-activity relationship studies led to the identification of thieno[2,3-d]pyrimidine 6a and thiazolo[5,4-d]pyrimidine 7a, which exhibited remarkable nanomolar PI3K potency, good antiproliferative activity, favorable pharmacokinetic properties and significant in vivo anti-cancer efficacy. Notably, thiazolo[5,4-d]pyrimidine 7a had better anti-cancer activity than thieno[2,3-d]pyrimidine 6a and is worthy of further pre-clinical evaluation for its use in cancer treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors

Related Publications

Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
October 2020, Molecules (Basel, Switzerland),
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
October 2023, European journal of medicinal chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
February 2018, Bioorganic & medicinal chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
July 2021, Bioorganic chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
August 2019, Chemistry & biodiversity,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
May 1992, Archiv der Pharmazie,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
July 2011, Bioorganic & medicinal chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
October 2009, Bioorganic & medicinal chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
November 2023, Future medicinal chemistry,
Yan Sun, and Rong Fu, and Songwen Lin, and Jingbo Zhang, and Ming Ji, and Yan Zhang, and Deyu Wu, and Kehui Zhang, and Hua Tian, and Mingyi Zhang, and Li Sheng, and Yan Li, and Jing Jin, and Xiaoguang Chen, and Heng Xu
September 2023, Pharmaceuticals (Basel, Switzerland),
Copied contents to your clipboard!